Aβ(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease

Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Portelius, Erik, Zetterberg, Henrik, Dean, Robert A., Marcil, Alexandre, Bourgeois, Philippe, Nutu, Magdalena, Andreasson, Ulf, Siemers, Eric, Mawuenyega, Kwasi G., Sigurdson, Wendy C., May, Patrick C., Paul, Steven M., Holtzman, David M., Blennow, Kaj, Bateman, Randall J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3609706/
https://ncbi.nlm.nih.gov/pubmed/22531418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-2012-120508
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak